0001209191-23-038842.txt : 20230621 0001209191-23-038842.hdr.sgml : 20230621 20230621172158 ACCESSION NUMBER: 0001209191-23-038842 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230616 FILED AS OF DATE: 20230621 DATE AS OF CHANGE: 20230621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dar Zavain CENTRAL INDEX KEY: 0001852075 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 231030882 MAIL ADDRESS: STREET 1: C/O LUX CAPITAL MANAGEMENT, LLC STREET 2: 1600 EL CAMINO REAL - SUITE 290 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-16 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001852075 Dar Zavain C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 0 0 0 0 Class A Common Stock 2023-06-16 4 A 0 12612 0.00 A 70181 D Stock Option (Right to Buy) 8.92 2023-06-16 4 A 0 25224 0.00 A 2024-06-16 2033-06-16 Class A Common Stock 25224 25224 D Stock Option (Right to Buy) 6.20 2023-06-14 2032-06-14 Class A Common Stock 36290 36290 D Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer. The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. /s/Jonathan Golightly, attorney-in-fact 2023-06-21